Krishnaveni Reddy to Female
This is a "connection" page, showing publications Krishnaveni Reddy has written about Female.
Connection Strength
0,472
-
Awareness of Heightened Sexual and Behavioral Vulnerability as a Trigger for PrEP Resumption Among Adolescent Girls and Young Women in East and Southern Africa. Curr HIV/AIDS Rep. 2023 12; 20(6):333-344.
Score: 0,086
-
''Ask the way from those who have walked it before"-Grandmothers' roles in health-related decision making and HIV pre-exposure prophylaxis use among pregnant and breastfeeding women in sub-Saharan Africa. PLoS One. 2022; 17(9):e0271684.
Score: 0,079
-
Ring-ing in the Future: Participant and Male Partner Perspectives Regarding Future Use of the Dapivirine Vaginal Ring for HIV Prevention. AIDS Behav. 2022 Jun; 26(6):1923-1932.
Score: 0,075
-
Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities. AIDS. 2020 03 15; 34(4):559-567.
Score: 0,066
-
"Killing two birds with one stone" - a qualitative study on women's perspectives on the dual prevention pill in Johannesburg, South Africa. BMC Womens Health. 2024 Aug 22; 24(1):462.
Score: 0,023
-
Examining Associations Between Mental Health, IPV Exposure, HIV Risk Behaviors, and PrEP Use in South African Women: An Analysis of Data from the Charisma Study. AIDS Behav. 2023 Jun; 27(6):2030-2040.
Score: 0,020
-
High HIV incidence among young women in South Africa: Data from a large prospective study. PLoS One. 2022; 17(6):e0269317.
Score: 0,019
-
Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N Engl J Med. 2021 03 04; 384(9):818-828.
Score: 0,018
-
Social harms in female-initiated HIV prevention method research: state of the evidence. AIDS. 2019 11 15; 33(14):2237-2244.
Score: 0,016
-
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 06 01; 376(22):2134-2146.
Score: 0,014
-
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373(27):2618-28.
Score: 0,012
-
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. J Clin Gastroenterol. 2015 Apr; 49(4):336-44.
Score: 0,012
-
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014 Apr 17; 370(16):1483-93.
Score: 0,011
-
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014 May 15; 370(20):1879-88.
Score: 0,011
-
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan 16; 370(3):211-21.
Score: 0,011